Alatrofloxacin
 | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | 76% (trovafloxacin) |
| Metabolism | Quickly hydrolyzed to trovafloxacin |
| Elimination half-life | 9 to 12 hours (trovafloxacin) |
| Excretion | Fecal and renal (trovafloxacin) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C26H25F3N6O5 |
| Molar mass | 558.509 g/mol g·mol−1 |
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
See also
References
- ^ "PubChem CID 5489474".
- ^ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |